Early risk screening for Alzheimer's disease

Key words:




Colloidal gold immunochromatography technology was used to qualitatively detect the Aβ concentration level in human urine, and the world's first AD urine test early screening reagent.


Product Features

  • Early screening:Screening of people at high risk of AD
  • Non-invasive:Non-invasive sampling urine test
  • Hypersensitivity:Detection sensitivity up to picogram level
  • Fast:Results can be reported 10 minutes after the sample is dropped
  • Convenient:Add 100uL urine, easy to detect
  • Accurate:The positive judgment value was 0.5ng/mL, and the detection rate was 95%


Product Application

  • It can be applied to the regular physical examination population over 45 years old;
  • Family history of dementia;
  • Memory impairment and suspected cognitive impairment;
  • Cardiovascular and cerebrovascular diseases and cerebrovascular injuries (stroke, cerebral hemorrhage, cerebral infarction, etc.);
  • Chronic diseases (hypertension, diabetes, hyperlipidemia, etc.), snoring and homocysteine deficiency;
  • Anxiety, depression, bad habits (smoking and drinking, lack of exercise in the middle of obesity, long-term lack of sleep, etc.).

Recommend Products

A biotechnology company focusing on key technologies for Alzheimer's disease (AD), a global medical challenge.

Explore more products